4RD.F MAAT PHARMA S.A. EO-1
- Market cap
- EUR 19.6M
- P/E
- -
- P/B
- 10.98x
- ROE
- -1,726.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4RD.F undervalued?
Graham numberThe Graham number of MAAT PHARMA S.A. EO-1 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MAAT PHARMA S.A. EO-1 fundamental analysis
No fundamental analysis for MAAT PHARMA S.A. EO-1 yet.
MAAT PHARMA S.A. EO-1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MAAT PHARMA S.A. EO-1
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic…
Full company profileMAAT PHARMA S.A. EO-1 financial statements
MAAT PHARMA S.A. EO-1 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 972K | 1.43M | 2.23M | 3.22M | 4.52M |
| Gross Profit | 806K | 1.09M | 1.66M | 1.97M | 3.12M |
| Operating Income | -8.89M | -13.6M | -19.9M | -28.4M | -29.7M |
| EBITDA | - | -13.1M | -18.4M | -26.3M | -28.1M |
| Net Income | -9.02M | -13.7M | -19.7M | -28.9M | -31.1M |
| EPS | -0.91 | -1.38 | -1.70 | -2.07 | -1.65 |
| Balance Sheet | |||||
| Total Assets | 49.4M | 44.7M | 42.9M | 38.5M | 44.6M |
| Total Liabilities | 9.56M | 17.9M | 22.5M | 28.2M | 42.8M |
| Shareholders' Equity | 39.9M | 26.8M | 20.5M | 10.3M | 1.80M |
| Cash & Short-term Investments | 43.3M | 35.2M | 24.3M | 20.2M | 24.9M |
| Cash Flow | |||||
| Operating Cash Flow | -7.93M | -12.6M | -18.7M | -22.0M | -15.7M |
| Capital Expenditure | 238K | 662K | 1.09M | 753K | 608K |
| Free Cash Flow | -8.17M | -13.3M | -19.8M | -22.8M | -16.3M |
| Ratios | |||||
| ROE | -22.6% | -51.1% | -96.3% | -279.6% | -1,726.6% |
| ROA | -18.2% | -30.7% | -45.9% | -75.1% | -69.7% |
| Net Profit Margin | -927.9% | -959.0% | -885.0% | -898.8% | -686.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MAAT PHARMA S.A. EO-1 dividends
MAAT PHARMA S.A. EO-1 has not paid dividends in the last 5 fiscal years.
Who owns MAAT PHARMA S.A. EO-1
- Insiders 22.06%
- Institutions 46.78%
- Public & others 31.16%
- Shares outstanding 18.8M
- Free float 11.0M
MAAT PHARMA S.A. EO-1 company profile
- Company name
- MAAT PHARMA S.A. EO-1
- Ticker
- 4RD.F
- ISIN
- FR0012634822
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 60
- Fiscal year end
- December
- Address
- 70 Avenue Tony Garnier, Lyon, France, 69007
- Phone
- 33 4 28 29 14 00
- Website
- maatpharma.com
About MAAT PHARMA S.A. EO-1
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. MaaT Pharma SA was incorporated in 2014 and is headquartered in Lyon, France.
MAAT PHARMA S.A. EO-1 management
10- Mr. Herve AffagardCEO, Co-Founder & Director · born 1974
- Dr. Joel Dore Ph.D.Co-Founder & Member of Scientific Advisory Board
- Mr. Pierre RimbaudCo-Founder
- Mr. Eric Soyer Ph.D.Chief Financial Officer · born 1966
- Ms. Carole SchwintnerTechnology Director & Chief Technology Officer
- Ms. Sheri Simmons Ph.D.Acting Chief Scientific Officer
- Guilhaume Debroas Ph.D.Head of Investor Relations
- Dr. Frederic Fasano M.B.A., Pharm.D.Chief Strategy & Corporate Development Officer · born 1968
- Ms. Sian CrouzetChief of Staff
- Dr. Emilie Plantamura Ph.D., Pharm.D.Deputy Chief Medical Officer